|
Apr 25
|
11 Oversold MidCap Stocks To Buy Now
|
|
Apr 24
|
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
|
|
Apr 23
|
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 22
|
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
|
|
Apr 18
|
Bruker to acquire Nanostring for $393M
|
|
Apr 10
|
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
|
|
Mar 26
|
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
|
|
Mar 21
|
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
|
|
Mar 13
|
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
|
|
Mar 13
|
11 Oversold Healthcare Stocks To Buy Right Now
|
|
Feb 15
|
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
|
|
Feb 15
|
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 15
|
10x Genomics Inc (TXG) Reports Solid Revenue Growth Amid Rising Operating Expenses in FY 2023
|
|
Feb 15
|
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
|
|
Feb 8
|
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Dec 21
|
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 20
|
10x Genomics Launches Xenium Catalyst Network
|
|
Dec 19
|
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 7
|
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
|